SOURCE: Threshold Pharmaceuticals

February 10, 2006 08:00 ET

Threshold to Present at BIO CEO & Investor Conference 2006

REDWOOD CITY, CA -- (MARKET WIRE) -- February 10, 2006 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Threshold's chief executive officer, is scheduled to present at the BIO CEO & Investor Conference 2006 on Tuesday, February 14th at 2:00 p.m. EST. The conference will be held at the Waldorf=Astoria Hotel in New York City.

About Threshold Pharmaceuticals

Threshold is a biotechnology company, with late stage clinical programs, focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor cells and abnormally proliferating cells, the Company is building a pipeline of drug candidates that hold promise to be more effective and less toxic to healthy tissues than conventional drugs. Threshold's initial clinical focus is the treatment of cancer and benign prostatic hyperplasia, or BPH, a disease afflicting tens of millions of men worldwide. For additional information, please visit our website (www.thresholdpharm.com).

Contact Information

  • Investor Contact:
    Denise T. Powell
    Sr. Director, Corporate Communications
    Threshold Pharmaceuticals, Inc.
    650-474-8206
    Email Contact

    Media Contact:
    Carolyn Bumgardner Wang
    WeissComm Partners, Inc.
    415-946-1065
    Email Contact